We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Phase I study of ch14.18 with granulocyte-macrophage colony-stimulating factor and interleukin-2 in children with neuroblastoma after autologous bone marrow transplantation or stem-cell rescue: a report from the Children's Oncology Group.
- Authors
Gilman, Andrew L; Ozkaynak, M Fevzi; Matthay, Katherine K; Krailo, Mark; Yu, Alice L; Gan, Jacek; Sternberg, Adam; Hank, Jacquelyn A; Seeger, Robert; Reaman, Gregory H; Sondel, Paul M
- Abstract
Recurrence of high-risk neuroblastoma is common despite multimodality therapy. ch14.18, a chimeric human/murine anti-G(D2) antibody, lyses neuroblastoma cells. This study determined the maximum tolerable dose (MTD) and toxicity of ch14.18 given in combination with interleukin-2 (IL-2) after high-dose chemotherapy (HDC)/stem-cell rescue (SCR). Biologic correlates including ch14.18 levels, soluble IL-2 receptor levels, and human antichimeric antibody (HACA) activity were evaluated.
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Vol 27, Issue 1, p85
- ISSN
1527-7755
- Publication type
Journal Article
- DOI
10.1200/JCO.2006.10.3564